Low Plasma Levels of Hyaluronic Acid Might Rule Out Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
05
2022
revised:
26
10
2022
accepted:
27
02
2023
medline:
28
4
2023
pubmed:
27
4
2023
entrez:
27
4
2023
Statut:
epublish
Résumé
Sinusoidal obstructive syndrome (SOS) is a potentially fatal complication secondary to hematopoietic stem cell transplant (HSCT) conditioning. Endothelial damage plasma biomarkers such as plasminogen activator inhibitor-1 (PAI-1), hyaluronic acid (HA), and vascular adhesion molecule-1 (VCAM1) represent potential diagnostic tools for SOS. We prospectively collected serial citrated blood samples (baseline, day 0, day 7, and day 14) in all adult patients undergoing HSCT at La Paz Hospital, Madrid. Samples were later analyzed by ELISA (enzyme-linked immunosorbent assay) for HA, VCAM1, and PAI-1 concentrations. During sixteen months, we prospectively recruited 47 patients. Seven patients (14%) were diagnosed with SOS according to the EBMT criteria for SOS/VOD diagnosis and received treatment with defibrotide. Our study showed a statistically significant elevation of HA on day 7 in SOS patients, preceding clinical SOS diagnosis, with a sensitivity of 100%. Furthermore, we observed a significant increase of HA and VCAM1 levels on day 14. Regarding risk factors, we observed a statistically significant association between SOS diagnosis and the fact that patients received 3 or more previous lines of treatment before HSCT. The early significant increase in HA levels observed opens the door to a noninvasive peripheral blood test which could have the potential to improve diagnosis and facilitate prophylactic and therapeutic management of SOS before clinical/histological damage is established.
Sections du résumé
Background
UNASSIGNED
Sinusoidal obstructive syndrome (SOS) is a potentially fatal complication secondary to hematopoietic stem cell transplant (HSCT) conditioning. Endothelial damage plasma biomarkers such as plasminogen activator inhibitor-1 (PAI-1), hyaluronic acid (HA), and vascular adhesion molecule-1 (VCAM1) represent potential diagnostic tools for SOS.
Methods
UNASSIGNED
We prospectively collected serial citrated blood samples (baseline, day 0, day 7, and day 14) in all adult patients undergoing HSCT at La Paz Hospital, Madrid. Samples were later analyzed by ELISA (enzyme-linked immunosorbent assay) for HA, VCAM1, and PAI-1 concentrations.
Results
UNASSIGNED
During sixteen months, we prospectively recruited 47 patients. Seven patients (14%) were diagnosed with SOS according to the EBMT criteria for SOS/VOD diagnosis and received treatment with defibrotide. Our study showed a statistically significant elevation of HA on day 7 in SOS patients, preceding clinical SOS diagnosis, with a sensitivity of 100%. Furthermore, we observed a significant increase of HA and VCAM1 levels on day 14. Regarding risk factors, we observed a statistically significant association between SOS diagnosis and the fact that patients received 3 or more previous lines of treatment before HSCT.
Conclusions
UNASSIGNED
The early significant increase in HA levels observed opens the door to a noninvasive peripheral blood test which could have the potential to improve diagnosis and facilitate prophylactic and therapeutic management of SOS before clinical/histological damage is established.
Identifiants
pubmed: 37101837
doi: 10.1155/2023/7589017
pmc: PMC10125768
doi:
Substances chimiques
Hyaluronic Acid
9004-61-9
Plasminogen Activator Inhibitor 1
0
Polydeoxyribonucleotides
0
Vascular Cell Adhesion Molecule-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7589017Informations de copyright
Copyright © 2023 Carmen De Ramón Ortiz et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interests. Raul Justo Sanz is currently an employee at Takeda Pharmaceutical, Spain, S.A.
Références
Bone Marrow Transplant. 2020 Mar;55(3):485-495
pubmed: 31576023
J Med Ultrason (2001). 2021 Jan;48(1):45-52
pubmed: 33398544
Blood. 1997 Mar 15;89(6):2184-8
pubmed: 9058743
Diagn Interv Imaging. 2014 Jan;95(1):11-5
pubmed: 24007769
Front Immunol. 2021 May 19;12:641427
pubmed: 34093530
Biol Blood Marrow Transplant. 2004 May;10(5):347-54
pubmed: 15111934
Biol Blood Marrow Transplant. 2018 Sep;24(9):1896-1900
pubmed: 29803752
Ann Surg Oncol. 2013 May;20(5):1462-9
pubmed: 23463086
Br J Haematol. 2020 Aug;190(4):508-519
pubmed: 32319084
Neurochem Res. 2015 May;40(5):1042-52
pubmed: 25868755
Bone Marrow Transplant. 2021 Oct;56(10):2326-2335
pubmed: 34253879
Blood. 2017 Jan 12;129(2):162-170
pubmed: 27827824
Biol Blood Marrow Transplant. 2018 Oct;24(10):2072-2080
pubmed: 29928989
EJHaem. 2020 Jul;1(1):219-229
pubmed: 32885223
Transplant Cell Ther. 2022 Nov;28(11):765.e1-765.e9
pubmed: 35953029
Blood. 2018 May 17;131(20):2193-2204
pubmed: 29622549
Bone Marrow Transplant. 2022 Aug;57(8):1338-1340
pubmed: 35614317
Transfus Apher Sci. 2020 Aug;59(4):102827
pubmed: 32522474
Bone Marrow Transplant. 2011 Dec;46(12):1495-502
pubmed: 21460864
Expert Rev Gastroenterol Hepatol. 2019 May;13(5):463-484
pubmed: 30895833
Biol Blood Marrow Transplant. 2010 Jul;16(7):1005-17
pubmed: 20167278
Biol Blood Marrow Transplant. 2010 Feb;16(2):157-68
pubmed: 19766729
Bone Marrow Transplant. 2016 Jul;51(7):906-12
pubmed: 27183098
Biol Blood Marrow Transplant. 2016 Mar;22(3):400-9
pubmed: 26431626
Bone Marrow Transplant. 2020 Mar;55(3):531-537
pubmed: 30181580
Transplantation. 2021 Apr 1;105(4):686-694
pubmed: 33273315
Front Immunol. 2020 Apr 03;11:489
pubmed: 32318059
Transplantation. 1987 Dec;44(6):778-83
pubmed: 3321587
Biol Blood Marrow Transplant. 2015 Oct;21(10):1739-45
pubmed: 26172478
Int J Hematol. 2021 Jul;114(1):94-101
pubmed: 33763826
Clin Drug Investig. 2022 Jun;42(6):465-476
pubmed: 35594010
Biol Blood Marrow Transplant. 2020 Oct;26(10):1770-1779
pubmed: 32593647
Bone Marrow Transplant. 2021 Apr;56(4):917-927
pubmed: 33208915
Bone Marrow Transplant. 2015 Jun;50(6):781-9
pubmed: 25798682
Lancet. 1999 Aug 14;354(9178):561-3
pubmed: 10470701
Haematologica. 2021 Feb 01;106(2):446-453
pubmed: 31974195
Br J Haematol. 2020 Aug;190(4):583-587
pubmed: 32157682
Ann Hematol. 2019 Jul;98(7):1733-1742
pubmed: 31053879
Br J Haematol. 2020 Sep;190(6):822-836
pubmed: 32133623
Bone Marrow Transplant. 2001 Mar;27(6):635-9
pubmed: 11319594
Clin Hematol Int. 2019 Mar 18;1(1):45-51
pubmed: 34595410
Hepatology. 1994 May;19(5):1171-81
pubmed: 8175139
Biol Blood Marrow Transplant. 2019 Jul;25(7):1271-1280
pubmed: 30797942
Cochrane Database Syst Rev. 2015 May 27;(5):CD009311
pubmed: 26017019
Hematology. 2003 Apr;8(2):91-5
pubmed: 12745658
Bone Marrow Transplant. 2021 Jan;56(1):175-184
pubmed: 32665674